Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...
Brooklyn biotech files 40-claim patent application covering a new active-ingredient combination for over-the-counter headache ...
The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...
Century Therapeutics (IPSC) analysis: autoimmune CAR-cell pivot, CNTY-813 Type 1 diabetes upside, cash burn cuts, rNPV fair ...
Legend Biotech (NASDAQ: LEGN) was one of the healthier healthcare stocks on the market as the trading week kicked off on ...
ORLANDO, FL / ACCESS Newswire / April 21, 2026 / RedChip Companies, an industry leader in investor relations, media, ...
The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...
Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...
But in the last three years, the company has sought to leverage its footholds in China and the U.S. to become a multinational ...
The deal for Kelonia Therapeutics is valued at $3.25 billion upfront.
ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results